US regulators have approved Novartis’ Gilenya to treat children and adolescents with relapsing forms of multiple sclerosis, making it the first disease-modifying therapy indicated for this patient group.
14th May 2018
NICE is now backing a trio of therapies to treat relapsing remitting forms of multiple sclerosis after price cuts enabled the cost regulator to endorse their routine use on the NHS.
14th May 2018
2018 marks 25 years since the first PharmaTimes Marketer of the Year competition took place, and in that time the competition has helped thousands of marketers across the industry hone their skills, advance their careers and keep up to date with very latest business thinking.
11th May 2018
Not only is this this three-stage competition free to enter, it’s also the only pharmaceutical sales awards where representatives are evaluated by their healthcare professional clients, before pitting them head-to-head in a real life challenge against their peers.
11th May 2018
The PharmaTimes Communications Team of the year competition is now open for entry, with two new categories offering yet more opportunities for forward thinking agencies!
11th May 2018
The PharmaTimes International Clinical Researcher of the Year Awards Ceremony & Gala Dinner is to take place next Thursday (17 May) at the Millenium Gloucester Hotel in London's Kensington.
11th May 2018
Janssen’s Tremfya has been recommended by NICE as a cost-effective treatment for plaque psoriasis.
11th May 2018
Eli Lilly is buying ARMO BioSciences in a deal valued at around $1.6 billion, to ramp up its immune-oncology pipeline.
11th May 2018
Scientists have made a major discovery having identified a mutation that gives cancer cells resistance to AstraZeneca’s Lynparza and other PARP inhibitors.
11th May 2018
Akcea Therapeutics’ volanesorsen has taken a step closer to becoming the first therapy on the US market for the ultra-rare rare lipid disorder familial chylomicronemia syndrome (FCS).
11th May 2018
A study published in the British Journal of General Practice has found that it is becoming increasingly difficult for patients to get appointments with their GP of choice.
10th May 2018
US regulators have rejected Lipocine’s Tlando, a testosterone replacement therapy for adult males with hypogonadism.
10th May 2018
Roche has revealed that a combination of Tecentriq and Cotellic tested in a late-stage trial failed to improve overall survival compared to regorafenib in patients with advanced metastatic colorectal cancer (CRC).
10th May 2018
GlaxoSmithKline has announced that its chief financial officer Simon Dingemans is to retire.
10th May 2018
The government has taken a u-turn on controversial data-sharing arrangements under which the NHS was able to hand over patient details to the Home Office for immigration tracking purposes.
10th May 2018
